254 related articles for article (PubMed ID: 20135590)
1. [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Saxer F; Dick W
Z Orthop Unfall; 2010 Jan; 148(1):26-30. PubMed ID: 20135590
[TBL] [Abstract][Full Text] [Related]
2. [Summary and perspectives. Rivaroxaban].
Albaladejo P
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
[TBL] [Abstract][Full Text] [Related]
3. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
4. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Kwong LM
Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
10. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
11. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Eriksson BI; Kakkar AK; Turpie AG; Gent M; Bandel TJ; Homering M; Misselwitz F; Lassen MR
J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Ageno W
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban, the first oral, direct factor Xa inhibitor.
Fassiadis N
Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
16. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Harenberg J; Marx S; Dahl OE; Marder VJ; Schulze A; Wehling M; Weiss C
Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Borris LC
Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
